Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. Decensi A, et al. Among authors: veronesi u. Clin Cancer Res. 2003 Oct 15;9(13):4722-9. Clin Cancer Res. 2003. PMID: 14581342 Clinical Trial.
Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.
Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurrida S, Costa A, De Palo G, Veronesi U. Chiesa F, et al. Among authors: veronesi u. Int J Cancer. 2005 Jul 1;115(4):625-9. doi: 10.1002/ijc.20923. Int J Cancer. 2005. PMID: 15700313 Free article. Clinical Trial.
Fenretinide and risk reduction of second breast cancer.
Decensi A, Zanardi S, Argusti A, Bonanni B, Costa A, Veronesi U. Decensi A, et al. Among authors: veronesi u. Nat Clin Pract Oncol. 2007 Feb;4(2):64-5. doi: 10.1038/ncponc0735. Nat Clin Pract Oncol. 2007. PMID: 17259924 Clinical Trial. No abstract available.
Plasma testosterone and prognosis of postmenopausal breast cancer patients.
Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Veronesi U, Formelli F. Micheli A, et al. Among authors: veronesi u. J Clin Oncol. 2007 Jul 1;25(19):2685-90. doi: 10.1200/JCO.2006.09.0118. Epub 2007 Jun 4. J Clin Oncol. 2007. PMID: 17548841
Plasma retinol and prognosis of postmenopausal breast cancer patients.
Formelli F, Meneghini E, Cavadini E, Camerini T, Di Mauro MG, De Palo G, Veronesi U, Berrino F, Micheli A. Formelli F, et al. Among authors: veronesi u. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):42-8. doi: 10.1158/1055-9965.EPI-08-0496. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19124479
Effect of fenretinide on ovarian carcinoma occurrence.
De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U. De Palo G, et al. Among authors: veronesi u. Gynecol Oncol. 2002 Jul;86(1):24-7. doi: 10.1006/gyno.2002.6663. Gynecol Oncol. 2002. PMID: 12079295 Clinical Trial.
Chemoprevention of breast cancer with fenretinide.
Veronesi U, De Palo G, Costa A, Formelli F, Decensi A. Veronesi U, et al. IARC Sci Publ. 1996;(136):87-94. IARC Sci Publ. 1996. PMID: 8791119 Review. No abstract available.
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U. De Palo G, et al. Among authors: veronesi u. Tumori. 1997 Nov-Dec;83(6):884-94. doi: 10.1177/030089169708300603. Tumori. 1997. PMID: 9526578 Clinical Trial.
480 results